Cargando…
Prognostic Value of Regression Rate of Plasma EBV DNA After Induction Chemotherapy for Stage II-IVA Nasopharyngeal Carcinoma
BACKGROUND/OBJECTIVE: We aimed to explore the prognostic value of regression rate (RR) of plasma Epstein–Barr virus (EBV) DNA after induction chemotherapy (IC) in patients with stages II–IVA nasopharyngeal carcinoma (NPC). METHODS: Eligible patients receiving IC followed by concurrent chemoradiother...
Autores principales: | Peng, Hao, Chen, Bin-bin, Wang, Xiao-hui, Mo, Yun-Xian, Han, Fei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319726/ https://www.ncbi.nlm.nih.gov/pubmed/34336675 http://dx.doi.org/10.3389/fonc.2021.689593 |
Ejemplares similares
-
Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma
por: Lan, Xiao-Wen, et al.
Publicado: (2016) -
A Nomogram for the Determination of the Necessity of Concurrent Chemotherapy in Patients With Stage II–IVa Nasopharyngeal Carcinoma
por: Yang, Kaixuan, et al.
Publicado: (2021) -
Efficacy and Safety of Concurrent Chemoradiotherapy Combined With Induction Chemotherapy or Adjuvant Chemotherapy in Patients With Stage II–IVA Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis and Meta-Analysis
por: Yang, Jie, et al.
Publicado: (2021) -
Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis
por: Lai, Lin, et al.
Publicado: (2021) -
Novel Plasma Proteomic Biomarkers for Early Identification of Induction Chemotherapy Beneficiaries in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Zhang, Shan-Qiang, et al.
Publicado: (2022)